- Home
- ATRA vs GDL Comparison
ATRA vs GDL Comparison
Compare ATRA & GDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATRA | GDL |
|---|---|---|
| Founded | 2012 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 99.1M | 94.9M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATRA | GDL |
|---|---|---|
| Price | $15.69 | $8.48 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 63.1K | 11.2K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.02% |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $151,930,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.98 | ★ N/A |
| Revenue Growth | ★ 51.27 | N/A |
| 52 Week Low | $5.01 | $7.65 |
| 52 Week High | $18.71 | $8.13 |
Technical Indicators
Market Signals| Indicator | ATRA | GDL |
|---|---|---|
| Relative Strength Index (RSI) | 60.46 | 47.80 |
| Support Level | $12.05 | $8.45 |
| Resistance Level | $15.12 | $8.52 |
| Average True Range (ATR) | 1.08 | 0.06 |
| MACD | 0.20 | -0.00 |
| Stochastic Oscillator | 93.44 | 41.18 |
Price Performance
Historical ComparisonAbout ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
About GDL GDL Fund The of Beneficial Interest
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.